Merrimack Pharmaceuticals Inc.
101 Binney Street
266 articles with Merrimack Pharmaceuticals Inc.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK
Pomerantz LLP is investigating claims on behalf of investors of Merrimack Pharmaceuticals, Inc..
The latest job cuts at Merrimack come about five months after the company culled 60 percent of its staff.
Safety update shows Phase 1 study unable to reach optimal therapeutic index for MM-310 due to continued observation of cumulative peripheral neuropathy
In the wake of a Complete Response Letter issued by the FDA, Trevana, Inc. is slashing one-third of its workforce. On Wednesday, Merrimack Pharmaceuticals also announced it was terminating 60 percent of its staff as the company narrows its research and development focus.
Merrimack Reports Third Quarter 2018 Financial Results and Provides Strategic Update Following Portfolio Review
Company to initiate corporate restructuring, including ~60% reduction in force and significant reduction in operating expenses; potential to extend runway into at least 2H 2022 to preserve ability to capture Ipsen milestones
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its third quarter 2018 investor conference call and webcast at 8:30 am ET on Wednesday, November 7, 2018.
Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to Futility
MM-121 did not improve progression free survival (PFS) in patients with non-small cell lung cancer (NSCLC)
The trial was evaluating MM-121 in combination with docetaxel, a chemotherapy drug, in patients with heregulin positive non-small cell lung cancer (NSCLC).
Merrimack Pharmaceuticals, Inc. today announced that it has received a $5 million milestone payment from Shire, triggered by the sale of ONIVYDE in the first major non-European, non-Asian country, pursuant to the terms of Merrimack's asset sale to Ipsen in 2017.
Merrimack Completes Enrollment in Randomized Phase 2 SHERLOC Study of MM-121 (seribantumab) in Non-Small Cell Lung Cancer (NSCLC)
Merrimack Pharmaceuticals, Inc. today announced that it has completed enrollment in its ongoing SHERLOC study, a Phase 2 clinical trial evaluating its lead investigational drug candidate, MM-121, in patients with heregulin positive NSCLC.
The U.S. Securities and Exchange Commission has leveled charges at a former Sangamo Therapeutics Inc. executive and others for an insider-trading scheme that netted more than $1.5 million in “illegal profits.”
$18 million milestone payment received from Shire; Company continues to strengthen cash position from non-dilutive sources
Schultz Chan, the former director of biostatistics at Cambridge-based Akebia Therapeutics and Songjiang Wang, a director of statistical programming at Merrimack Pharmaceuticals (MACK) were convicted of insider trading by a federal grand jury in Boston.
Non-dilutive financing strengthens cash positio
Although it’s great to report on successful clinical trial results, the reality is that only about one in 10 drugs make it to approval. With that number in mind, here are a couple companies reporting problematic clinical trials today.
Precision medicine company names Chief Medical Officer, Chief Business Officer and Chief Technology Officer.
Merrimack Pharmaceuticals, Inc. announced that the company will host its first quarter 2018 investor conference call and webcast at 8:30 am ET on Tuesday, May 8, 2018.
Merrimack Pharmaceuticals announced it is expanding enrollment in a Phase II lung cancer study.
Merrimack Pharmaceuticals Inc. announced its fourth quarter and full year 2017 financial results for the period ended December 31, 2017.
Randomized Phase 2 study accrual raised to 100 patients; data still expected later this year.